Intrafamilial Phenotypic Variability in Friedreich Ataxia Associated With a G130V Mutation in the FRDA Gene

Dominick McCabe
Adelaide and Meath Hospital

Nicholas Wood
National Hospital fo

Fergus Ryan
Technological University Dublin, fergus.x.ryan@tudublin.ie

Michael Hanna
National Hospital for Neurology and Neurosurgery, London

Sean Connolly
St. James’ Hospital, Dublin

Follow this and additional works at: https://arrow.tudublin.ie/scschbioart

Recommended Citation

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License
Intrafamilial Phenotypic Variability in Friedreich Ataxia Associated With a G130V Mutation in the FRDA Gene

Dominick McCabe∗  Nicolas Wood†  Fergus Ryan Dr.‡
Michael Hanna**  Sean Connolly††  David Moore‡‡
Janice Redmond§  David Barton¶  Raymond Murphy∥

∗Adelaide and Meath Hospital
†National Hospital for Neurology and Neurosurgery, London
‡Dublin Institute of technology, fergus.x.ryan@dit.ie
**National Hospital for Neurology and Neurosurgery, London
††St. James’ Hospital, Dublin
‡‡Adelaide and Meath Hospital
§St. James’ Hospital, Dublin
¶National Centre For Medical Genetics, Dublin
∥Adelaide and Meath Hospital

This paper is posted at ARROW@DIT.
http://arrow.dit.ie/ahfrcart/1
Attribution-NonCommercial-ShareAlike 1.0

You are free:

- to copy, distribute, display, and perform the work
- to make derivative works

Under the following conditions:

- Attribution.
  You must give the original author credit.

- Non-Commercial.
  You may not use this work for commercial purposes.

- Share Alike.
  If you alter, transform, or build upon this work, you may distribute the
  resulting work only under a license identical to this one.

For any reuse or distribution, you must make clear to others the license terms
of this work. Any of these conditions can be waived if you get permission from
the author.

Your fair use and other rights are in no way affected by the above.

This work is licensed under the Creative Commons Attribution-NonCommercial-
ShareAlike License. To view a copy of this license, visit:

- URL (human-readable summary):
  http://creativecommons.org/licenses/by-nc-sa/1.0/

- URL (legal code):
  http://creativecommons.org/worldwide/uk/translated-license
Intrafamilial Phenotypic Variability in Friedreich Ataxia Associated With a G130V Mutation in the FRDA Gene

Dominick J. H. McCabe, MRCPI; Nicholas W. Wood, FRCP; Fergus Ryan, PhD; Michael G. Hanna, MD; Sean Connolly, MD; David P. Moore, MRCPI; Janice Redmond, MD; David E. Barton, PhD; Raymond P. Murphy, FRCP

Background: Most patients with Friedreich ataxia (FA) have a GAA trinucleotide repeat expansion in intron 1 of the FA gene (FRDA) on both arms of chromosome 9. However, some patients are compound heterozygotes and harbor a GAA expansion on one allele and a point mutation on the other. Compound heterozygous patients with FA who have a GAA expansion and a G130V mutation have been reported to have an atypical phenotype with a slow disease progression, minimal or no ataxia, or gait spasticity.

Objective: To describe intrafamilial phenotypic variability in a GAA expansion/G130V mutation compound heterozygous family with FA.

Setting: Tertiary referral university hospital setting.

Patients and Methods: A 34-year-old man presented to our hospital with a 24-year history of stiff legs and mild unsteadiness of gait. Clinical examination showed a spastic paraparesis with normal to pathologically brisk deep tendon reflexes and mild left upper limb ataxia. His 27-year-old sister presented with a slowly progressive early-onset ataxic syndrome. She had ataxia of gait, mild to severe limb ataxia, and reduced or absent deep tendon reflexes, but no evidence of spasticity on examination.

Results: Neurophysiologic investigations showed evidence of a sensory axonal neuropathy, and molecular genetic analysis showed that both siblings were compound heterozygotes with a GAA expansion and a G130V mutation.

Conclusions: This report confirms that compound heterozygous patients with FA who have a GAA expansion and a G130V mutation may present with an ataxic phenotype and that intrafamilial phenotypic variability in these pedigrees can occur. It also emphasizes the importance of performing molecular genetic analysis for the GAA trinucleotide expansion in patients presenting with a spastic paraparesis of undetermined etiology, especially when there is neurophysiologic evidence of a sensory axonal neuropathy.

Arch Neurol. 2002;59:296-300

Friedreich ataxia (FA) is a progressive neurodegenerative disorder with a prevalence of approximately 1 in 50,000 in European populations. According to Harding’s mandatory clinical diagnostic criteria for FA, affected individuals should have an age at onset younger than 25 years and definitely younger than 27 years, ataxia of gait, ataxia of all 4 limbs, lower limb areflexia, and a mode of inheritance consistent with an autosomal recessive disorder. Dysarthria was present in all patients with a disease duration of at least 10 years, and 96% of patients had neurophysiologic evidence of a sensory axonal neuropathy in Harding’s original series. The majority of patients with FA, including some individuals with an atypical phenotype, have a GAA trinucleotide repeat expansion in intron 1 of the FRDA gene on both arms of chromosome 9q 13-21. Normal alleles contain between 6 and 34 GAA repeats, whereas FA alleles carry between 66 and 1700 repeats. Some individuals are compound heterozygotes with a GAA trinucleotide repeat expansion on one allele and a point mutation on the other, and Bidichandani and colleagues identified one such missense mutation, the G130V mutation, in exon 4 of the FRDA gene in 1997. Although the phenotype may vary between family members harboring 2 GAA expansions, intrafamilial phenotypic variability has rarely been described in compound heterozygous FA pedigrees with a GAA expansion on one allele and a G130V mutation on the other.
REPORT OF CASES

CASE 1

A 34-year-old right-handed man (subject III:1; Figure, A) presented to our hospital with a 24-year history of stiff legs and unsteadiness while walking; his clinical history has been briefly alluded to previously. He was the offspring of two unrelated Irish parents who had no symptoms of ataxia or neurologic disease.

He had been well until 10 years of age, when he developed a febrile illness with vomiting, nocturnal confusion, agitation, and arthralgia during a 3-week period. He was treated with a course of oral amoxicillin, and although his symptoms improved within weeks, he complained of lower limb aching pains for the following 2 months. Subsequently, he noted stiffness in both legs and incoordination of the left more than right leg, with difficulty correcting his posture if pushed over. He had no subjective limb weakness, sensory symptoms, or sphincter disturbance. The unsteadiness while walking gradually increased, so that he required assistance to walk within 6 years and began using crutches 10 years after symptom onset. Although his leg stiffness subjectively increased during the 5-year period before the current examination, he was still ambulatory with the aid of 2 crutches. He had no cardiac symptoms and no history of diabetes and was not taking any medication at the time of assessment. One of his sisters had been given a clinical diagnosis of FA at 20 years of age (patient III:2), but there was no other family history of ataxia.

General physical examination disclosed a very mild thoracic scoliosis, fixed flexion contractures at the left knee and hip joints, and pes planus, but was otherwise normal. The findings on neurologic examination are outlined in the Table; the patient had a spastic paraparesis with normal to pathologically brisk reflexes throughout, bilateral extensor plantar responses, and minimal ataxia. He did not fulfill all of Harding’s mandatory clinical diagnostic criteria for FA, and he did not have dysarthria 24 years after disease onset.

Results of routine hematologic and biochemical investigations were normal, as were levels of blood glucose, vitamin E, vitamin B₁₂, and folate. Thyroid function test results, autoantibody screening results, and treponemal serologic findings were normal or negative. His electrocardiogram was generally of low amplitude and showed p mitrale, but was otherwise normal, and a 2-dimensional transthoracic echocardiogram was normal. Magnetic resonance images of the brain were normal, but magnetic resonance images of the cervical spine showed a right-sided posterior disc protrusion at C₄-₅, posteriorly displacing the cord at this level, but without evidence of signal abnormality within the cord.

CASE 2

The sister (subject III:2; Figure, A) of subject III:1 was assessed at 27 years of age. She had had normal developmental milestones, but had transient ataxia and vomiting for a few days associated with a febrile illness at 5 years of age. Ten years later, she developed a sore throat, arthralgia, and fever and was diagnosed as having rheumatic fever. Subsequent to this illness, she had mild persistent left leg weakness and mild ataxia of gait, but was able to run and continued to play sports. The ataxia of gait increased slowly until 19 years of age, and after a recurrence of rheumatic fever at 20 years of age, she was clinically diagnosed as having FA. Her unsteadiness while walking increased during the 7-year period before presentation, but she was still able to walk without assistance at the time of assessment.

General physical examination showed a mild thoracic scoliosis and left pes cavus, but was otherwise normal. Her neurologic findings are outlined in the Table. In contrast to her clinically affected brother (subject III:1), she had no evidence of spasticity or limb weakness, and she had reduced or absent deep tendon reflexes and more pronounced ataxia of gait and limbs. It was of interest that she did not have dysarthria at least 12 years after disease onset either.
with the following primers: FRDA G130Vf: 5’-AAGCAATGATGACAAAGTGCTAAC; FRDA G130Vr: 5’-CTCCACCCAGTTGACGTTAGTCACA. The 25-µL reaction contained 200 ng of DNA, 100 ng of each primer, 200µM deoxynucleotide mixture (dNTP), and standard PCR buffer containing 1.5 mM magnesium chloride and 1 U of Taq polymerase (Gibco BRL, Life Technologies, Paisley, Scotland). The PCR conditions were 94°C for 5 minutes; followed by 35 cycles of 30 seconds at 94°C, 59°C, and 72°C, respectively, and a final extension at 72°C for 5 minutes. The underlined T in the FRDA G130Vr primer results in the generation of a Hin cII site in the presence of the G130V mutation. After PCR, 10 µL of the PCR product was digested for a minimum of 2 hours with 10 U of Hin cII (New England Biolabs Inc, Beverly, Mass) with the use of conditions recommended by the manufacturer. The digestion products were visualized on a 2.5% agarose gel containing ethidium bromide, 0.5 µg/µL (Figure, B). Wild-type sequences from subjects not carrying the G130V mutation result in an uncut PCR product of 104 base pairs (bp). The G130V mutation results in 2 additional products of 77 and 27 bp, but the 27-bp product is generally not visible on the agarose gel. This analysis showed a G130V mutation within exon 4 of the FRDA gene in the first family reported to be heterozygous for the GAA trinucleotide repeat expansion and a G130V mutation exhibited an atypical FA phenotype. Although the clinical details of the 3 affected members were not published in detail, the 2 older siblings presented with leg weakness in the early teens, with a gradual disease progres-

Results of routine hematologic and biochemical investigations were normal, and levels of blood glucose, vitamin B₁₂, and folate and treponemal serologic findings were normal or negative. Vitamin E levels were mildly reduced at 10.7 µmol/L (reference range, 11.5-35 µmol/L). An electrocardiogram showed T-wave inversion in leads III and V₁, but no other signs of cardiomyopathy. Two-dimensional transthoracic echocardiography at age 23 years had shown concentric left ventricular hypertrophy with good left ventricular function.

### MOLECULAR GENETIC ANALYSIS

In view of the clinical diagnosis of FA in subject III:2, polymerase chain reaction (PCR) analysis for the GAA trinucleotide repeat expansion was performed by means of established techniques. Subject III:1 was estimated to have approximately 954 GAA repeats and subject III:2 to have 917 GAA repeats on one allele of chromosome 9, but the GAA repeat number on the other allele was normal in both subjects. The diffuse trinucleotide repeat expansion was performed by means of established techniques.

Both patients were presumed to be compound heterozygotes, G130V point mutation testing was performed with the following primers: FRDA G130Vf: 5’-AAGCAATGATGACAAAGTGCTAAC; FRDA G130Vr: 5’-CTCCACCCAGTTGACGTTAGTCACA. The 25-µL reaction contained 200 ng of DNA, 100 ng of each primer, 200µM deoxynucleotide mixture (dNTP), and standard PCR buffer containing 1.5 mM magnesium chloride and 1 U of Taq polymerase (Gibco BRL, Life

### Clinical Characteristics of the 2 Affected Patients

<table>
<thead>
<tr>
<th>Clinical Details</th>
<th>Subject III:1</th>
<th>Subject III:2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at examination, y</td>
<td>34</td>
<td>27</td>
</tr>
<tr>
<td>Disease duration, y</td>
<td>24</td>
<td>12†</td>
</tr>
<tr>
<td>Gait</td>
<td>Spastic scissoring</td>
<td>Ataxic</td>
</tr>
<tr>
<td>Titubation</td>
<td>No</td>
<td>Mild</td>
</tr>
<tr>
<td>OA/SP*</td>
<td>Right SP</td>
<td>No</td>
</tr>
<tr>
<td>Nystagmus</td>
<td>Very mild horizontal gaze–evoked</td>
<td>No; jerky pursuit movements</td>
</tr>
<tr>
<td>Dysarthria</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Upper limb tone</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Lower limb tone</td>
<td>Severe spasticity</td>
<td>Normal</td>
</tr>
<tr>
<td>Pyramidal weakness</td>
<td>Not in arms/severe in legs</td>
<td>No</td>
</tr>
<tr>
<td>Upper limb reflexes</td>
<td>++ to +++</td>
<td>Absent</td>
</tr>
<tr>
<td>Lower limb reflexes</td>
<td>++++ Right and left knee jerks, ++ left ankle jerk/++ right ankle jerk</td>
<td>+ Right knee jerk (reinforced), absent left knee/ankle jerks</td>
</tr>
<tr>
<td>Extensor plantar response</td>
<td>Bilateral</td>
<td>Bilateral</td>
</tr>
<tr>
<td>Upper limb ataxia</td>
<td>Mild left</td>
<td>Mild right and left</td>
</tr>
<tr>
<td>Lower limb ataxia</td>
<td>Indeterminate; spasticity</td>
<td>Severe right and left</td>
</tr>
<tr>
<td>Cerebellar rebound</td>
<td>Bilateral</td>
<td>Bilateral</td>
</tr>
<tr>
<td>Sensation in upper limbs</td>
<td>Impaired vibration</td>
<td>Normal</td>
</tr>
<tr>
<td>Sensation in lower limbs</td>
<td>Impaired pinprick, temperature, vibration</td>
<td>Impaired vibration and joint position</td>
</tr>
<tr>
<td>Distal amyotrophy</td>
<td>Legs</td>
<td>No</td>
</tr>
<tr>
<td>Pes cavus</td>
<td>No; pes planus</td>
<td>Left and varus deformity</td>
</tr>
<tr>
<td>Nerve conduction studies</td>
<td>Sensory axonal neuropathy</td>
<td>Sensory axonal neuropathy</td>
</tr>
</tbody>
</table>

*OA indicates optic atrophy; SP, suspicious pallor of the optic disc; +, reduced deep tendon reflex; ++, normal deep tendon reflex; ++++, brisk deep tendon reflex; and ++++, brisk deep tendon reflex with clonus. Subject III:2 was considered to have had an age at onset of the disease at 15 years because of the presence of persistent symptoms after this age.

†Subject III:2 was considered to have onset at age 15 years because of the presence of persistent symptoms after this age.

The first family reported to be heterozygous for the GAA trinucleotide repeat expansion and a G130V mutation exhibited an atypical FA phenotype. Although the clinical details of the 3 affected members were not published in detail, the 2 older siblings presented with leg weakness in the early teens, with a gradual disease progres-

**COMMENT**

The first family reported to be heterozygous for the GAA trinucleotide repeat expansion and a G130V mutation exhibited an atypical FA phenotype. Although the clinical details of the 3 affected members were not published in detail, the 2 older siblings presented with leg weakness in the early teens, with a gradual disease progres-
posed that the G130V mutation leads to the production of an abnormal frataxin protein with modified or reduced function. The resulting combination of “frataxin deficiency,” caused by a GAA expansion, and “frataxin dysfunction,” secondary to a G130V mutation, may account for the difference in phenotypic expression between patients with FA who are compound heterozygotes with a GAA expansion and a G130V mutation and those with 2 GAA expansions. In addition, the degree of frataxin dysfunction may vary depending on the point mutation present in the FRDA gene. It has been postulated that the G130V mutation causes more subtle loss of frataxin function than another missense mutation (I154F) that is associated with a typical FA phenotype.

Although compound heterozygotes with FA who have a GAA expansion and a G130V mutation commonly present with a predominantly spastic phenotype, this report confirms that these patients may present with an ataxic phenotype instead, with reduced or absent deep tendon reflexes. In addition, intrafamilial phenotypic variability in these pedigrees may occur. It also emphasizes the importance of performing molecular genetic analysis for the GAA trinucleotide repeat expansion in patients presenting with a spastic paraparesis of undetermined etiology, especially when there is neurophysiologic evidence of sensory axonal neuropathy that is typically seen in FA.

Accepted for publication September 7, 2001.

Author contributions: Study concept and design (Drs McCabe and Wood); acquisition of data (Drs McCabe, Ryan, Hanna, Connolly, Moore, and Barton); analysis and interpretation of data (Drs McCabe, Wood, Ryan, Hanna, Connolly, Moore, Redmond, Barton, and Murphy); drafting of the manuscript (Drs McCabe, Ryan, and Hanna); critical revision of the manuscript for important intellectual content (Drs McCabe, Wood, Ryan, Hanna, Connolly, Moore, Redmond, Barton, and Murphy); administrative, technical, or material support (Drs McCabe, Ryan, and Barton); study supervision (Drs Wood, Hanna, Connolly, Moore, Redmond, Barton, and Murphy).

From the Departments of Neurology (Drs McCabe and Murphy) and Cardiology (Dr Moore), The Adelaide and Meath Hospital, incorporating The National Children’s Hospital, Dublin, Ireland; Department of Clinical Neurology, Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, England (Drs McCabe, Wood, and Hanna); Department of Biological Sciences, Dublin Institute of Technology (Dr Ryan); Departments of Clinical Neurophysiology (Dr Connolly) and Neurology (Dr Redmond), St James’s Hospital, and National Centre for Medical Genetics (Drs Ryan and Barton) and University College Dublin Department of Paediatrics (Dr Barton), Our Lady’s Hospital for Sick Children, Dublin.

Dr McCabe’s research is currently funded by a grant from the Brain Research Trust, London, England.

Corresponding author and reprints: Dominick J. H. McCabe, MRCP, Department of Clinical Neurology, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, England (e-mail: d.mccabe@ion.ucl.ac.uk).
REFERENCES